Somewhat Positive Press Coverage Somewhat Unlikely to Impact Acorda Therapeutics (ACOR) Stock Price

News stories about Acorda Therapeutics (NASDAQ:ACOR) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Acorda Therapeutics earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 44.8543446076981 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:

Acorda Therapeutics (ACOR) traded up $0.20 during trading on Friday, hitting $24.05. The stock had a trading volume of 561,803 shares, compared to its average volume of 776,325. Acorda Therapeutics has a 52-week low of $13.60 and a 52-week high of $33.00. The company has a quick ratio of 2.40, a current ratio of 2.77 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $1,114.92, a price-to-earnings ratio of -19.88 and a beta of 1.63.

Several equities analysts have weighed in on the company. Raymond James Financial lowered Acorda Therapeutics from a “market perform” rating to an “underperform” rating and increased their price objective for the company from $7.00 to $13.00 in a report on Thursday, November 16th. Zacks Investment Research lowered Acorda Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. JPMorgan Chase & Co. set a $24.00 price objective on Acorda Therapeutics and gave the company a “hold” rating in a report on Tuesday, October 31st. HC Wainwright reissued a “buy” rating and set a $31.00 price objective (down from $34.00) on shares of Acorda Therapeutics in a report on Wednesday, January 17th. Finally, Oppenheimer began coverage on Acorda Therapeutics in a report on Thursday, November 9th. They set a “market perform” rating and a $27.00 price objective for the company. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $21.35.

In other news, insider Burkhard Blank sold 11,050 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $20.53, for a total value of $226,856.50. Following the completion of the transaction, the insider now directly owns 33,150 shares of the company’s stock, valued at $680,569.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider David Lawrence sold 31,000 shares of the firm’s stock in a transaction on Friday, January 19th. The stock was sold at an average price of $27.58, for a total value of $854,980.00. Following the completion of the transaction, the insider now directly owns 5,275 shares of the company’s stock, valued at $145,484.50. The disclosure for this sale can be found here. 7.90% of the stock is owned by company insiders.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Acorda Therapeutics (ACOR) Stock Price” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.com-unik.info/2018/02/10/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-acorda-therapeutics-acor-stock-price.html.

About Acorda Therapeutics

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Insider Buying and Selling by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit